



Published in final edited form as:

Lab Chip. 2016 July 05; 16(14): 2644–2653. doi:10.1039/c6lc00598e.

Engineering a perfusable 3D human liver platform from iPS cells

Arnout Schepers^{1,2}, Cheri Li^{1,2}, Arnav Chhabra^{1,2}, Benjamin Tschudy Seney^{1,2}, and Sangeeta Bhatia^{1,2,3,4,5,6,*}

¹Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139

²Institute for Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA 02139

³Electrical Engineering and Computer Science, Massachusetts Institute of Technology, Cambridge, MA 02139

⁴Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA 02115

⁵Broad Institute of Massachusetts Institute of Technology and Harvard, Cambridge, MA 02139


⁶Howard Hughes Medical Institute, Cambridge, MA 02139

Abstract

In vitro models of human tissue are crucial to our ability to study human disease as well as develop safe and effective drug therapies. Models of single organs in static and microfluidic culture have been established and shown utility for modeling some aspects of health and disease; however, these systems lack multi-organ interactions that are critical to some aspects of drug metabolism and toxicity. Thus, as part of a consortium of researchers, we have developed a liver chip that meets the following criteria: (1) employs human iPS cells from a patient of interest, (2) cultures cells in perfusable 3D organoids, and (3) is robust to variations in perfusion rate so as to be compatible in series with other specialized tissue chips (e.g. heart, lung). In order to achieve this, we describe methods to form hepatocyte aggregates from primary and iPS-derived cells, alone and in co-culture with support cells. This necessitated a novel culture protocol for the interrupted differentiation of iPS cells that permits their removal from a plated surface and aggregation while maintaining phenotypic hepatic functions. In order to incorporate these 3D aggregates in a perfusable platform, we next encapsulated the cells in a PEG hydrogel to prevent aggregation and overgrowth once on chip. We adapted a C-trap chip architecture from the literature that enabled robust loading with encapsulated organoids and culture over a range of flow rates. Finally, we characterize the liver functions of this iHep organoid chip under perfusion and demonstrate a lifetime of at least 28 days. We envision that such this strategy can be generalized to other microfluidic tissue models and provides an opportunity to query patient-specific liver responses in vitro.

*Corresponding Author: Sangeeta N. Bhatia, Address: 500 Main Street, 76-453, Cambridge, MA 02142, USA, Phone: 617-253-0893, Fax: 617-324-0740, sbhatia@mit.edu.

Graphical Abstract



Introduction

The liver is responsible for a multitude of essential functions, including biosynthesis of plasma proteins, energy metabolism, biotransformation of drugs and toxins, and the production of bile^{1, 2}. The biotransformation of chemicals, which can have both required and/or toxic outcomes in the case of administered drugs, is catalyzed by cytochrome P450 enzymes (CYPs)³. CYPs are conserved amongst mammals, though the expression of different isoforms, their metabolizing specificity, and products are species-specific^{4, 5}. These inter-species divergences complicate the extrapolation of animal safety data, resulting in many lead compounds that fail in patients due to either a lack of efficacy or drug-induced toxicity^{6–8}. One approach to overcome the cross-species testing divide has been to develop a variety of *in vitro* models of human liver, with the aim to achieve more accurate predictions of potential adverse effects of candidate drugs^{9–11}. In some of these efforts, human hepatocytes benefit from co-culture with liver- or non-liver-derived stromal cells in order to retain their phenotypic functions for a period of weeks *in vitro*^{12–17}. In addition to determining the cellular makeup of human models, various architectures have been attempted. 3D culture models have the potential to illuminate aspects of biology not observed in 2D; however, dense 3D constructs often suffer from limited nutrient transport, particularly oxygen^{18–38}. Continuous media circulation in microfluidic devices can address some of these transport issues, and also offers the possibility to analyze circulation of metabolites to downstream target organs.

Advances in microfabrication techniques have led to several perfused liver models. However, most platforms require complex loading protocols or a period of on chip stabilization^{39–44}, which can lead to a high rate of variability and limits their scale up. Furthermore, although organ-organ interactions can provide valuable insights in drug toxicity, connecting and scaling different organ modules with different dimensions and flow rates remains problematic⁴⁵. In addition to engineering challenges, finding a robust cell source is essential for reproducing organ specific functions. Functionally, isolated primary human hepatocytes are the cell type of choice for *in vitro* drug metabolism and toxicology assessments^{46, 47}. However, limited availability of donor material makes it difficult to source enough cells and to examine the effect of genetic polymorphisms in CYP enzymes. The derivation of hepatocytes from iPSC cells has been proposed as an unlimited supply of hepatic cells with diverse genetic backgrounds, with the added opportunity to test patient-

specific toxicity^{48–51}. Currently, iPSC derived hepatocyte-like cells (iHeps) mostly resemble fetal-stage hepatocytes⁵², but additional maturation methods have been described^{53–55} and iHeps have been used to successfully predict drug toxicity^{55–57}. The combination of organs-on-chips with iPSC technologies will be an important factor for future success.

In this report, we describe a perfused human liver model that is compatible with both primary hepatocytes and iHeps. We phenotypically stabilized primary human hepatocytes by aggregating them with 3T3-J2 fibroblasts in pyramidal microwells^{58, 59}. Aggregates were encapsulated into small polyethylene glycol (PEG) microtissues^{60, 61}, which maintained inducible CYP activity. By trapping microtissues in a microfluidic device we were able to provide sufficient transport of oxygen and nutrients to establish albumin secretion for more than 28 days. Microtissues could be cultured under a range of flow rates, providing flexibility for systems integration. In addition, we developed a differentiation protocol to generate functional iHeps in 3D and stabilize them in microtissues. The iHep aggregates are comprised of cells resembling hepatocytes and biliary cells, have inducible CYP activity and show long term function on-chip. This combination provides the opportunity to query patient-specific drug responses.

Experimental

Cell culture and aggregation

Cryopreserved primary human hepatocytes (lot Hu1434 & Hu4175) were obtained from Life technologies. 3T3-J2 murine fibroblasts were a gift from Howard Green of Harvard Medical School⁶² and were maintained in DMEM with 10% bovine serum (Invitrogen), 10 U/mL penicillin, and 10 mg/mL streptomycin. Cells were cultured in a 5% CO₂ humidified incubator at 37°C. Hepatocyte culture medium consisted of Dulbecco's Modified Eagle Medium (DMEM; Invitrogen) with 10% fetal bovine serum (Invitrogen), 0.5 U/mL insulin (Lilly), 7 ng/mL glucagon (Bedford Laboratories), 7.5 µg/mL hydrocortisone (Sigma), 10 U/mL penicillin (Invitrogen), and 10 mg/mL streptomycin (Invitrogen).

Plates with arrays of square pyramidal microwells, 100µm or 400µm side-wall dimension, were fabricated as described previously⁵⁹, or purchased (Aggrewell, Stem Cell Technologies). Pyramidal microwells were pretreated with 5% pluronic F-127 (Sigma); plates were centrifuged at 2000g for 5 minutes to remove air bubbles, incubated for 60 minutes and washed twice in DMEM before seeding of cells. All other centrifugation steps were done at 50 g for 5 min.

iPS cells were differentiated into iHeps according to Si-Tayeb et al.⁴⁸ with a few adjustments. At day 8 of the differentiation, cells were dissociated using Enzyme free dissociation buffer (Gibco) and aggregated in square pyramidal microwells with 400 µm side-wall dimensions. At day 12, aggregates were encapsulated in PEG-DA hydrogels. At day 22, cells were treated once with 20 µM maturation molecule FH1⁵³.

Encapsulation

For microfluidic encapsulation, cell aggregates were pelleted (50 g, 5 min), and resuspended in PEG-DA pre-polymer. The pre-polymer solution consisted of 100 mg/mL PEG-diacrylate (20 kDa; Laysan Bio) in heavy DMEM (DMEM adjusted to have a specific gravity of 1.06 by OptiPrep density medium; Sigma) with 1:100 v/v photoinitiator (100 mg/mL Irgacure 2959, Ciba, in n-vinyl pyrrolidone; Sigma). The cell suspension was loaded into a syringe and injected into the droplet generator. Simultaneously, Fluorinert[®] FC-40 (Sigma) containing 0.5% w/v Krytox 157 FSH surfactant (DuPont) was injected into the device as an oil phase. Using a 60 μ m nozzle, the aqueous cell suspension was broken into droplets of cells and pre-polymer in oil, which were then continuously polymerized on-chip by exposure to UV light (320–390 nm, 500 mW/cm², ~0.5 s; Lumen Dynamics) before exiting the device. Polymerized microtissues from the droplet generator were separated from oil and any un-polymerized components by retaining them on a 40 μ m cell strainer (BD Falcon) and flushing them with media. After washing, microtissues were collected from the filter and resuspended in hepatocyte medium, and loaded in C-trap microfluidic devices or cultured in 40 μ m strainer caps (BD Falcon) as inserts for 24-well plates. C-trap devices were loaded using a 1ml syringe (BD) with a 23 gauge dispensing needle (McMaster). After trapping the microtissues, the inlet of the device was connected to a media reservoir and the outlet was connected to a peristaltic pump (Ismatec IP-N 24), to pull the media through the device into a collection tube (Fig. S1).

Device fabrication

Microfluidic devices were designed in AutoCAD. Topographically patterned polydimethylsiloxane (PDMS; Dow Corning) devices were fabricated using standard photolithographic methods. Silicon wafers were spin coated at 1200 rpm with SU-8 2050 photoresist (Microchem) and features were patterned using 50K DPI photolithography masks (Fineline imaging). Patterned masters were treated with (tridecafluoro-1,1,2,2-tetrahydrooctyl)-1-trichlorosilane (Sigma) for 30 minutes in a vacuum desiccator. PDMS devices were cast from the masters and inlets were made using a 20G needle (McMaster-Carr) before binding the devices to glass microslides (VWR) by plasma oxidation. Droplet generator devices were coated with Aquapel (PPG Industries) and dried under vacuum prior to use.

Biochemical assays

Secreted albumin in flow-through from the devices was quantified by an enzyme-linked immunosorbent assay (ELISA) kit (Bethyl Labs) according to the manufacturer's instructions. For enzyme induction experiments, microtissues were pretreated with inducers or inhibitors for 72 hours. Stock solutions were prepared in dimethyl sulfoxide (DMSO) and diluted at 1:1000 for final concentrations of 50 μ M omeprazole (Sigma), 25 μ M rifampin (Sigma), 25 μ M 8-methoxypsoralen (Sigma), 50 μ M Quinidine (Sigma), 50 μ M ThioTEPA (Sigma). Phenobarbital (Sigma) was dissolved at 40 mM in deionized water and diluted to a final concentration of 1 mM. Vehicle controls were pretreated for 72 hours with DMSO or water. CYP450 activity was assessed by HPLC quantification of metabolites or with luminogenic P450-Glo[™] CYP450 assay kits (Promega) according to vendor instructions for

non-lytic assays using cultured cells. Processed medium samples were collected from each strainer of microtissues or from flow-through from microfluidic devices and luciferin metabolites were measured on a luminometer (1 s; Tecan).

Immunohistochemistry, live-dead staining, and imaging

Cell viability was examined using Calcein AM (5 $\mu\text{g/mL}$) and Propidium Iodide (2 $\mu\text{g/mL}$) fluorescent stains (Molecular Probes; incubated with cells for 30 min, 37°C) to stain live and dead cells. iHep aggregates were fixed in 4% paraformaldehyde and stained for albumin (Sigma A6684), HNF4 α (Santa Cruz sc-8987) and HNF1 β (Santa Cruz sc-7411) according to Snippert et al.⁶³. Images were acquired using a Nikon Ellipse TE200 inverted fluorescence microscope and CoolSnap-HQ Digital CCD Camera. ImageJ was used to uniformly adjust brightness/contrast, pseudocolor, and merge images.

Statistical analysis and simulations

Data are presented as mean \pm standard deviation. Samples were compared using one-way ANOVA, with p-values of <0.05 considered statistically significant. Statistical significance in figures is represented as follows: $P>0.05 = \text{ns}$, $P 0.05 = *$, $P 0.01 = **$, $P 0.001 = ***$. Theoretical flow profiles were generated using the single-phase laminar flow module on COMSOL Multiphysics. The inputs to the model consisted of a constant fluid velocity at the inlet, zero pressure at the outlet and no-slip boundary condition at the edges. With water implemented as the bulk medium, the shear rate was determined as a function of the distance from each cell-trap and was multiplied by the dynamic viscosity to obtain the shear stress.

Results and discussion

This article presents a microfluidic perfusion system for hepatocyte culture. The design was prompted by the need for a system that cultures cells in perfusable 3D organoids, is robust to variations in perfusion rate and is compatible with iPSC derived hepatocytes.

Hepatocyte aggregation

To model human liver function we aimed to generate a platform as simple, robust, and reproducible as possible. Hepatocytes are the main functional cells of the liver, and previous work has shown that their function can be stabilized *in vitro* by co-culture with supportive stromal cells, i.e. murine 3T3-J2 fibroblasts^{14, 47}. To generate 3D co-cultures, hepatocytes were aggregated with 3T3-J2s (Fig. 1A). Specifically, single cell suspensions with a 3:1 ratio of cryopreserved human hepatocytes and 3T3-J2s were seeded into plates with tightly packed square pyramidal microwells with 100 μm side-wall dimensions⁵⁹. Due to the sloping sidewalls of the microwells, centrifugation caused cells to condense at the bottom of the microwells. After condensation, cells were allowed to aggregate for 24 hours. When seeded at a density of ~ 15 cells per microwell, cryopreserved human hepatocytes co-cultured with 3T3-J2s formed compact aggregates with a diameter of approximately 60 μm (Fig. 1C). In accordance with previous findings from our lab⁵⁸, the aggregation efficiency of hepatocytes cultured without 3T3-J2s was low under these conditions.

Encapsulation of aggregates into microtissues

To avoid uncontrolled growth and aggregation into large structures that would exceed the oxygen and nutrient diffusion limit (Fig. S2), we proceeded to encapsulate the hepatic aggregates in hydrogel. Hydrogel encapsulation of parenchymal hepatocytes and non-parenchymal cells has been shown to aid in long-term preservation of functionality of hepatic constructs¹⁷. This step also protects the aggregates from handling associated with loading them on-chip. To generate uniform, non-degradable hydrogels we used PEG-DA, a photopolymerizable macromer which is widely used in tissue engineering due to its non-immunogenicity and resistance to protein absorption⁶⁴. One day after aggregation, aggregates of hepatocytes and fibroblasts were resuspended at a density of 2×10^6 aggregates/mL in PEG-DA pre-polymer, and injected into a water-in-oil phase droplet generator (Fig. 1B). The droplet size was controlled by changing the ratio between the water and oil phase⁶⁰. Using a flow rate of 800 μ L/h for oil and 200 μ L/h for the cell suspension we generated 100 μ m diameter microtissues at ~800 microtissues per minute. Staining with Calcein AM and Propidium Iodide shows that membrane integrity was preserved 24 hours after polymerization of the microtissues (Fig 1D, Fig. S3).

Cytochrome P450 enzyme activity of microtissues post-encapsulation

Co-culture can prolong important hepatic functions, i.e. CYPs are essential for the biotransformation of many drugs, and their function is rapidly lost when hepatocytes are cultured *in vitro* without stabilization⁶⁵. To assess the functionality of our stabilized human microtissues, we tested the enzymatic activity of prominent CYP isoforms after one week of culture. Microtissues were incubated for 72 hours with selected drugs with established CYP induction or inhibition profiles, and assayed for the presence of drug metabolites in the media. We observed a 350-fold induction of CYP1A2 activity by omeprazole, an AhR (aryl-hydrocarbon receptor) activator (Fig. 1E). Similarly, CYP2A6 was induced by rifampin, a pregnane X receptor (PXR) activator, and by the PXR/constitutive androstane receptor (CAR) activator, phenobarbital. In addition, CYP2A6 activity could be inhibited by 8-methoxypsoralen (Fig. 1F). CYP3A4 is the most abundant isoform of hepatic CYPs, yet levels quickly decrease in *in vitro* culture⁶⁶. In the microtissues, CYP3A4 could be induced by rifampin after one week in culture (Fig. 1G). The ~20-fold induction is consistent with the estimated *in vivo* inducibility reported by Ged et al.⁶⁷, where there was an 18-fold increase in CYP3A4 protein levels in liver biopsies after a 4 day rifampin treatment. Genetic polymorphisms in CYP enzymes cause an extensive inter-individual variation in human drug metabolism^{68–70}. By using microtissues generated from different hepatocyte donors, we were able to observe patient-specific differences in CYP activity, which may arise from genotypic differences (Fig. 1H–J).

Integrating microtissues on-chip

Continuous media circulation can improve nutrient transport and is essential for multi-organ integration. To perfuse our liver model at different flow rates, we designed a microfluidic device to restrain the microtissues while minimizing shear stress (Fig. 2A). The device contains an array of C-shaped traps, inspired by designs for single cell entrapment^{71, 72}, and can easily be connected to peristaltic pumps. Theoretical flow profiles were generated to

model the media flow in the device (Fig. 2B), and the shear stress was calculated at different points in the device (Fig. 2C). As anticipated, the shear stress is lowest within the traps. The shape and spacing of the traps was optimized to minimize shear stress at physiological flow rates (Fig. 2D), while maximizing the total number of traps in the device. Because the hepatocytes are pre-stabilized in microtissues, they can easily be integrated in the devices without additional cell stabilization on-chip. The devices are optically clear, which allows for easy loading and real-time monitoring. The devices are fabricated out of PDMS, which is permeable to oxygen and gives a sufficient oxygen supply through the device, regardless of the flow rate (See supplemental calculation). Loading the device resulted in an average of 11 microtissues per trap (Fig. 2E). Viability of the microtissues was ~80% upon loading the devices and perfusion culture did not affect the cell health, as measured by AlamarBlue (Fig. S4). Next, we set out to determine the flexibility of compatible flow rates for our system. The human liver contains about 240 billion cells and receives ~25% of the cardiac output ⁷³. Using allometric scaling, a cardiac output of ~5L/min would translate to a flow rate of ~15ul/hr for a microliver with 35K cells. However, in multi-organ systems, flow rate adjustments may be required to connect different modules and ensure a suitable physiological contribution to the coupled system. For example flow rates of 20–300 ul/hr have been reported for other organs on-chips containing lung or heart ^{74, 75}. We perfused our microtissues in devices with media at flow rates ranging from 24–540ul/h and assessed hepatic function by measuring albumin secretion as a biomarker in the perfusate. Although the shear stress in the C-traps increases linearly with the flow rate (Fig. 2F), we observed no significant difference in albumin levels at different flow rates (Fig. 2G), which provides flexibility to connect our device to other organ modules. Next we set out to determine whether hydrogel encapsulation contributed to protect the aggregates from shear stress. It has been described that perfusion of un-encapsulated hepatocytes entrapped using gravity based aggregation leads to disaggregation of cells from the surface of spheroids ⁴⁴. Although our design of the C-traps reduces the shear stress within these structures, the remaining shear stress may still affect the cells. At 540ul/h, our model predicts a shear stress up to 0.13 dyn/cm² within the C-traps (Fig. S5). It has been shown that hepatocytes show reduced functionality under ‘high’ (5–21dyn/cm²) vs ‘low’ shear stress (0.01–0.33dyn/cm²) ⁷⁶. Furthermore, perfusion with 0.34 dyn/cm² has been shown to reduce cell adhesion compared to lower shear stress conditions of 0.03 dyn/cm² ⁷⁷. To test the importance of encapsulation we loaded our devices with aggregates that were not encapsulated and perfused them at flow rates of 24 and 540ul/h. The un-encapsulated aggregates washed out of the C-traps and albumin levels dropped at the higher flow rate of 540ul/h (Fig. 2H–I), demonstrating the advantage of encapsulation in our perfusion system. We then looked at long term function by sampling our microtissue-loaded devices every other day. We detected persistent albumin production on-chip for 28 days using microtissues from two different donors (Fig. 2J). Furthermore, coumarin metabolism in perfused devices was higher than in static strainers (Fig. 2K).

Functional iPSC derived hepatocytes on-chip

The development of an *in vitro* platform that depends on access to a limited supply of cadaveric liver cells will still be restricted in its usefulness. To overcome this cell sourcing issue, and to expand the application of our liver model with respect to disease model

generation and genotype-specific drug screening, we sought to incorporate iHeps into our platform. Aggregating mature iHeps differentiated using an established four-stage approach⁴⁸ was ineffective, as the cells lost their hepatic phenotype upon dissociation, possibly due to disrupted cell-cell junctions⁵⁴. To generate 3D cultures with functional iHeps, we interrogated a series of modified differentiation – aggregation – encapsulation protocols^{48, 52, 54, 78}, and observed that a brief time window for the transition from 2D to 3D culture was essential for the prolonged functionality of the resulting iHep microtissues (Fig. 3A). Dissociating and aggregating the differentiating cells at a density of ~100 cells per aggregate during the hepatic specification phase yielded functional iHeps in 3D, whereas aggregation during the hepatoblast expansion or hepatic maturation phase yielded microtissues with reduced functionality (Fig. 3B). Hepatic specified iPSC cells, dissociated at day 8, formed compact aggregates (Fig. 3C). At day 22 of the differentiation, we confirmed the hepatic identity of cells within the iHep aggregates by positive staining for hepatocyte markers HNF4 α and albumin (Fig. 3D). Interestingly, iHep aggregates also contained cells that stained positive for biliary marker HNF1 β , indicating that the aggregates represent a mixed population of differentiated cell types. This heterogeneity is also seen in iHeps in 2D culture and in other iPSC derived tissues^{48, 79, 80}, where the additional cell types may supplement the roles played by supporting cell types in more systematic co-culture models. Fruitful iHep aggregates that were aggregated at day 8 showed inducible CYP1A1 and CYP2C9 activity at day 22 of their differentiation (Fig. 4A–B). The CYP inducibility was lower than in aggregates comprised of primary hepatocytes, consonant with studies performed in 2D culture⁸¹. Next we set out to incorporate iHep aggregates on-chip. iHeps continue to proliferate and without encapsulation they eventually overgrew the device (Fig. S2). To confine their growth, aggregates were encapsulated during the hepatoblast expansion phase (Fig. 4C). This approach yielded viable microtissues (Fig. 4D), which showed robust albumin secretion on-chip for 3 weeks (Fig. 4E).

Conclusions

We have developed a human liver-on-a-chip model compatible with perfusion under a range of flow rates. Co-cultured hepatocytes were encapsulated in hydrogel droplets to form microtissues with stable hepatic function, e.g. albumin secretion and metabolic activity. Theoretical modeling was done to design a microfluidic device containing C shaped traps to confine encapsulated microtissues and achieve stable function under a range of flow rates, providing flexibility for integration with other organ modules. On-chip perfusion enabled albumin secretion over 28 days. Aggregation and encapsulation of iPSC cells during their differentiation towards hepatocytes yielded microtissues that depicted stable albumin production on-chip and inducible CYP activity, opening the door for patient-specific drug screening.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank Dr Heather Fleming for critical reading of the manuscript and Stephen Duncan (Medical University of South Carolina) for iPS cell lines. This work was supported by a grant from the National Institutes of Health (UH3 EB017103), and, in part, by the Koch Institute Support (core) Grant P30-CA14051 from the National Cancer Institute. The J2-3T3 fibroblast cell line was kindly provided by Howard Green (Harvard). A.S. is funded by the Dutch Cancer Society. S.N.B. is an HHMI investigator.

References

1. Hewitt NJ, Lecluyse EL, Ferguson SS. *Xenobiotica*. 2007; 37:1196–1224. [PubMed: 17968743]
2. Bhatia SN, Underhill GH, Zaret KS, Fox JJ. *Sci Transl Med*. 2014; 6:245sr242.
3. Wrighton SA, Stevens JC. *Crit Rev Toxicol*. 1992; 22:1–21. [PubMed: 1616599]
4. Shih H, Pickwell GV, Guenette DK, Bilir B, Quattrochi LC. *Hum Exp Toxicol*. 1999; 18:95–105. [PubMed: 10100022]
5. Martignoni M, Groothuis GM, de Kanter R. *Expert Opin Drug Metab Toxicol*. 2006; 2:875–894. [PubMed: 17125407]
6. Olson H, Betton G, Robinson D, Thomas K, Monro A, Kolaja G, Lilly P, Sanders J, Sipes G, Bracken W, Dorato M, Van Deun K, Smith P, Berger B, Heller A. *Regul Toxicol Pharmacol*. 2000; 32:56–67. [PubMed: 11029269]
7. Pritchard JF, Jurima-Romet M, Reimer ML, Mortimer E, Rolfe B, Cayen MN. *Nat Rev Drug Discov*. 2003; 2:542–553. [PubMed: 12815380]
8. DiMasi JA, Grabowski HG, Hansen RW. *N Engl J Med*. 2015; 372:1972. [PubMed: 25970070]
9. Wrighton SA, Vandenbranden M, Stevens JC, Shipley LA, Ring BJ, Rettie AE, Cashman JR. *Drug Metab Rev*. 1993; 25:453–484. [PubMed: 8313838]
10. Soldatow VY, Lecluyse EL, Griffith LG, Rusyn I. *Toxicol Res (Camb)*. 2013; 2:23–39. [PubMed: 23495363]
11. Bale SS, Verneti L, Senutovitch N, Jindal R, Hegde M, Gough A, McCarty WJ, Bakan A, Bhushan A, Shun TY, Golberg I, DeBiasio R, Usta OB, Taylor DL, Yarmush ML. *Exp Biol Med* (Maywood). 2014; 239:1180–1191. [PubMed: 24764241]
12. Fraczek J, Bolleyn J, Vanhaecke T, Rogiers V, Vinken M. *Arch Toxicol*. 2013; 87:577–610. [PubMed: 23242478]
13. Begue JM, Guguen-Guillouzo C, Pasdeloup N, Guillouzo A. *Hepatology*. 1984; 4:839–842. [PubMed: 6434390]
14. Bhatia SN, Balis UJ, Yarmush ML, Toner M. *FASEB J*. 1999; 13:1883–1900. [PubMed: 10544172]
15. Guillouzo A. *Environ Health Perspect*. 1998; 106(Suppl 2):511–532. [PubMed: 9599700]
16. Khetani SR, Szulgit G, Del Rio JA, Barlow C, Bhatia SN. *Hepatology*. 2004; 40:545–554. [PubMed: 15349892]
17. Yamada M, Utoh R, Ohashi K, Tatsumi K, Yamato M, Okano T, Seki M. *Biomaterials*. 2012; 33:8304–8315. [PubMed: 22906609]
18. Miranda JP, Leite SB, Muller-Vieira U, Rodrigues A, Carrondo MJ, Alves PM. *Tissue Eng Part C Methods*. 2009; 15:157–167. [PubMed: 19072051]
19. Brophy CM, Luebke-Wheeler JL, Amiot BP, Khan H, Rimmel RP, Rinaldo P, Nyberg SL. *Hepatology*. 2009; 49:578–586. [PubMed: 19085959]
20. Griffin SJ, Houston JB. *Drug Metab Dispos*. 2005; 33:115–120. [PubMed: 15608354]
21. Vanhaecke T, Rogiers V. *Methods Mol Biol*. 2006; 320:209–227. [PubMed: 16719393]
22. Dunn JC, Tompkins RG, Yarmush ML. *Biotechnol Prog*. 1991; 7:237–245. [PubMed: 1367596]
23. Richert L, Binda D, Hamilton G, Viollon-Abadie C, Alexandre E, Bigot-Lasserre D, Bars R, Coassolo P, LeCluyse E. *Toxicol In Vitro*. 2002; 16:89–99. [PubMed: 11812644]
24. Moghe PV, Cogger RN, Toner M, Yarmush ML. *Biotechnol Bioeng*. 1997; 56:706–711. [PubMed: 18642343]

25. Berthiaume F, Moghe PV, Toner M, Yarmush ML. *FASEB J.* 1996; 10:1471–1484. [PubMed: 8940293]
26. Messner S, Agarkova I, Moritz W, Kelm JM. *Arch Toxicol.* 2013; 87:209–213. [PubMed: 23143619]
27. Glicklis R, Shapiro L, Agbaria R, Merchuk JC, Cohen S. *Biotechnol Bioeng.* 2000; 67:344–353. [PubMed: 10620265]
28. Kostadinova R, Boess F, Applegate D, Suter L, Weiser T, Singer T, Naughton B, Roth A. *Toxicol Appl Pharmacol.* 2013; 268:1–16. [PubMed: 23352505]
29. Lazar A, Mann HJ, Rimmel RP, Shatford RA, Cerra FB, Hu WS. *In Vitro Cell Dev Biol Anim.* 1995; 31:340–346. [PubMed: 7633671]
30. Koebe HG, Pahernik S, Eyer P, Schildberg FW. *Xenobiotica.* 1994; 24:95–107. [PubMed: 8017092]
31. Nishikawa Y, Tokusashi Y, Kadohama T, Nishimori H, Ogawa K. *Exp Cell Res.* 1996; 223:357–371. [PubMed: 8601413]
32. Pampaloni F, Reynaud EG, Stelzer EH. *Nat Rev Mol Cell Biol.* 2007; 8:839–845. [PubMed: 17684528]
33. Griffith LG, Swartz MA. *Nat Rev Mol Cell Biol.* 2006; 7:211–224. [PubMed: 16496023]
34. Bhatia SN, Ingber DE. *Nat Biotechnol.* 2014; 32:760–772. [PubMed: 25093883]
35. Glicklis R, Merchuk JC, Cohen S. *Biotechnol Bioeng.* 2004; 86:672–680. [PubMed: 15137079]
36. Mehta G, Mehta K, Sud D, Song JW, Bersano-Begley T, Futai N, Heo YS, Mycek MA, Linderman JJ, Takayama S. *Biomed Microdevices.* 2007; 9:123–134. [PubMed: 17160707]
37. Catapano G. *Int J Artif Organs.* 1996; 19:18–35. [PubMed: 8641815]
38. Au SH, Chamberlain MD, Mahesh S, Sefton MV, Wheeler AR. *Lab Chip.* 2014; 14:3290–3299. [PubMed: 24984750]
39. Lee PJ, Hung PJ, Lee LP. *Biotechnol Bioeng.* 2007; 97:1340–1346. [PubMed: 17286266]
40. Toh YC, Zhang C, Zhang J, Khong YM, Chang S, Samper VD, van Noort D, Huttmacher DW, Yu H. *Lab Chip.* 2007; 7:302–309. [PubMed: 17330160]
41. Domansky K, Inman W, Serdy J, Dash A, Lim MH, Griffith LG. *Lab Chip.* 2010; 10:51–58. [PubMed: 20024050]
42. Goral VN, Hsieh YC, Petzold ON, Clark JS, Yuen PK, Faris RA. *Lab Chip.* 2010; 10:3380–3386. [PubMed: 21060907]
43. Hegde M, Jindal R, Bhushan A, Bale SS, McCarty WJ, Golberg I, Usta OB, Yarmush ML. *Lab Chip.* 2014; 14:2033–2039. [PubMed: 24770663]
44. Lee SA, No dY, Kang E, Ju J, Kim DS, Lee SH. *Lab Chip.* 2013; 13:3529–3537. [PubMed: 23657720]
45. Wikswo JP, Curtis EL, Eagleton ZE, Evans BC, Kole A, Hofmeister LH, Matloff WJ. *Lab Chip.* 2013; 13:3496–3511. [PubMed: 23828456]
46. Godoy P, Hewitt NJ, Albrecht U, Andersen ME, Ansari N, Bhattacharya S, Bode JG, Bolleyn J, Borner C, Böttger J, Braeuning A, Budinsky RA, Burkhardt B, Cameron NR, Camussi G, Cho CS, Choi YJ, Craig Rowlands J, Dahmen U, Damm G, Dirsch O, Donato MT, Dong J, Dooley S, Drasdo D, Eakins R, Ferreira KS, Fonsato V, Fraczek J, Gebhardt R, Gibson A, Glanemann M, Goldring CE, Gómez-Lechón MJ, Groothuis GM, Gustavsson L, Guyot C, Hallifax D, Hammad S, Hayward A, Häussinger D, Hellerbrand C, Hewitt P, Hoehme S, Holzhütter HG, Houston JB, Hrach J, Ito K, Jaeschke H, Keitel V, Kelm JM, Kevin Park B, Kordes C, Kullak-Ublick GA, LeCluyse EL, Lu P, Luebke-Wheeler J, Lutz A, Maltman DJ, Matz-Soja M, McMullen P, Merfort I, Messner S, Meyer C, Mwinyi J, Naisbitt DJ, Nussler AK, Olinga P, Pampaloni F, Pi J, Pluta L, Przyborski SA, Ramachandran A, Rogiers V, Rowe C, Schelcher C, Schmich K, Schwarz M, Singh B, Stelzer EH, Stieger B, Stöber R, Sugiyama Y, Tetta C, Thasler WE, Vanhaecke T, Vinken M, Weiss TS, Widera A, Woods CG, Xu JJ, Yarborough KM, Hengstler JG. *Arch Toxicol.* 2013; 87:1315–1530. [PubMed: 23974980]
47. Khetani SR, Bhatia SN. *Nat Biotechnol.* 2008; 26:120–126. [PubMed: 18026090]
48. Si-Tayeb K, Noto FK, Nagaoka M, Li J, Battle MA, Duris C, North PE, Dalton S, Duncan SA. *Hepatology.* 2010; 51:297–305. [PubMed: 19998274]

49. Song Z, Cai J, Liu Y, Zhao D, Yong J, Duo S, Song X, Guo Y, Zhao Y, Qin H, Yin X, Wu C, Che J, Lu S, Ding M, Deng H. *Cell Res.* 2009; 19:1233–1242. [PubMed: 19736565]
50. Ma X, Duan Y, Tschudy-Seney B, Roll G, Behbahan IS, Ahuja TP, Tolstikov V, Wang C, McGee J, Khoobyari S, Nolte JA, Willenbring H, Zern MA. *Stem Cells Transl Med.* 2013; 2:409–419. [PubMed: 23681950]
51. Inoue H, Nagata N, Kurokawa H, Yamanaka S. *EMBO J.* 2014; 33:409–417. [PubMed: 24500035]
52. Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. *Biotechnol Adv.* 2014; 32:504–513. [PubMed: 24440487]
53. Shan J, Schwartz RE, Ross NT, Logan DJ, Thomas D, Duncan SA, North TE, Goessling W, Carpenter AE, Bhatia SN. *Nat Chem Biol.* 2013; 9:514–520. [PubMed: 23728495]
54. Gieseck RL, Hannan NR, Bort R, Hanley NA, Drake RA, Cameron GW, Wynn TA, Vallier L. *PLoS One.* 2014; 9:e86372. [PubMed: 24466060]
55. Berger DR, Ware BR, Davidson MD, Allsup SR, Khetani SR. *Hepatology.* 2015; 61:1370–1381. [PubMed: 25421237]
56. Takayama K, Kawabata K, Nagamoto Y, Kishimoto K, Tashiro K, Sakurai F, Tachibana M, Kanda K, Hayakawa T, Furue MK, Mizuguchi H. *Biomaterials.* 2013; 34:1781–1789. [PubMed: 23228427]
57. Ware BR, Berger DR, Khetani SR. *Toxicol Sci.* 2015; 145:252–262. [PubMed: 25716675]
58. Stevens KR, Ungrin MD, Schwartz RE, Ng S, Carvalho B, Christine KS, Chaturvedi RR, Li CY, Zandstra PW, Chen CS, Bhatia SN. *Nat Commun.* 2013; 4:1847. [PubMed: 23673632]
59. Ungrin MD, Joshi C, Nica A, Bauwens C, Zandstra PW. *PLoS One.* 2008; 3:e1565. [PubMed: 18270562]
60. Li CY, Stevens KR, Schwartz RE, Alejandro BS, Huang JH, Bhatia SN. *Tissue Eng Part A.* 2014; 20:2200–2212. [PubMed: 24498910]
61. Chen AA, Underhill GH, Bhatia SN. *Integr Biol (Camb).* 2010; 2:517–527. [PubMed: 20820630]
62. Rheinwald JG, Green H. *Cell.* 1975; 6:331–343. [PubMed: 1052771]
63. Snippet HJ, Schepers AG, Delconte G, Siersema PD, Clevers H. *Nat Protoc.* 2011; 6:1221–1228. [PubMed: 21799490]
64. Drury JL, Mooney DJ. *Biomaterials.* 2003; 24:4337–4351. [PubMed: 12922147]
65. Rodríguez-Antona C, Donato MT, Boobis A, Edwards RJ, Watts PS, Castell JV, Gómez-Lechón MJ. *Xenobiotica.* 2002; 32:505–520. [PubMed: 12160483]
66. Bowen WP, Carey JE, Miah A, McMurray HF, Munday PW, James RS, Coleman RA, Brown AM. *Drug Metab Dispos.* 2000; 28:781–788. [PubMed: 10859152]
67. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, Michel H, Beaune P, Maurel P. *Br J Clin Pharmacol.* 1989; 28:373–387. [PubMed: 2590599]
68. Zhou SF, Liu JP, Chowbay B. *Drug Metab Rev.* 2009; 41:89–295. [PubMed: 19514967]
69. Ingelman-Sundberg M, Sim SC, Gomez A, Rodriguez-Antona C. *Pharmacol Ther.* 2007; 116:496–526. [PubMed: 18001838]
70. Zanger UM, Klein K, Saussele T, Blievernicht J, Hofmann MH, Schwab M. *Pharmacogenomics.* 2007; 8:743–759. [PubMed: 17638512]
71. Di Carlo D, Wu LY, Lee LP. *Lab Chip.* 2006; 6:1445–1449. [PubMed: 17066168]
72. Skelley AM, Kirak O, Suh H, Jaenisch R, Voldman J. *Nat Methods.* 2009; 6:147–152. [PubMed: 19122668]
73. Bianconi E, Piovesan A, Facchin F, Beraudi A, Casadei R, Frabetti F, Vitale L, Pelleri MC, Tassani S, Piva F, Perez-Amodio S, Strippoli P, Canaider S. *Ann Hum Biol.* 2013; 40:463–471. [PubMed: 23829164]
74. Huh D, Matthews BD, Mammoto A, Montoya-Zavala M, Hsin HY, Ingber DE. *Science.* 2010; 328:1662–1668. [PubMed: 20576885]
75. Zhang B, Montgomery M, Chamberlain MD, Ogawa S, Korolj A, Pahnke A, Wells LA, Massé S, Kim J, Reis L, Momen A, Nunes SS, Wheeler AR, Nanthakumar K, Keller G, Sefton MV, Radisic M. *Nat Mater.* 2016

76. Tilles AW, Baskaran H, Roy P, Yarmush ML, Toner M. *Biotechnol Bioeng.* 2001; 73:379–389. [PubMed: 11320508]
77. Noh JK, Jung JG, Jang EM, Lee JH, Park HJ, Kim YA, Jung SM, Kwon CH, Lee DH, Lee SK. *Transplant Proc.* 2012; 44:1116–1119. [PubMed: 22564640]
78. Takebe T, Sekine K, Enomura M, Koike H, Kimura M, Ogaeri T, Zhang RR, Ueno Y, Zheng YW, Koike N, Aoyama S, Adachi Y, Taniguchi H. *Nature.* 2013; 499:481–484. [PubMed: 23823721]
79. Itoh M, Umegaki-Arao N, Guo Z, Liu L, Higgins CA, Christiano AM. *PLoS One.* 2013; 8:e77673. [PubMed: 24147053]
80. Burridge PW, Matsa E, Shukla P, Lin ZC, Churko JM, Ebert AD, Lan F, Diecke S, Huber B, Mordwinkin NM, Plews JR, Abilez OJ, Cui B, Gold JD, Wu JC. *Nat Methods.* 2014; 11:855–860. [PubMed: 24930130]
81. Yu Y, Liu H, Ikeda Y, Amiot BP, Rinaldo P, Duncan SA, Nyberg SL. *Stem Cell Res.* 2012; 9:196–207. [PubMed: 22885101]




Figure 1. Fabrication of modular liver microtissues

A) Primary hepatocytes and 3T3-J2 fibroblasts were centrifuged into pyramidal micro-wells (3:1 ratio, ~15 cells per pyramid) and allowed to aggregate for 1 day. **B)** On day 1, cell aggregates were resuspended in PEG-DA pre-polymer, injected into a water-in-oil droplet generator and continuously polymerized on-chip by exposure to a low dose of UV light. **C)** Hepatocytes alone did not aggregate, whereas co-cultures with 3T3-J2 fibroblasts formed compact aggregates. **D)** Encapsulated aggregates were tested for viability one day after encapsulation by staining with Calcein AM (green; live) and Propidium Iodide (red; dead). Scale bars represent 100µm. **E–J)** Microtissues maintained human specific CYP activity. Microtissues were cultured in strainers and treated with known perturbing agents or control media for 72 hours, starting at day 5 after encapsulation. On day 8, the metabolizing activity was measured by HPLC quantification of metabolites specific for each CYP isoform. Values represent averages of biological triplicates, error bars show standard deviation. **E)** Cyp1A2 activity evaluated by 7-ethoxyresorufin metabolism, when induced by omeprazole **F)** Cyp2A6 activity evaluated by coumarin metabolism to coumarin 7-hydroxylase in response to induction by rifampin and phenobarbital, or inhibition by 8-methoxypsoralen. **G)** Induction of CYP3A4 activity by Rifampin using testosterone as a specific substrate. **H–J)** Comparison of enzyme activity in microtissues generated from two different donors. **H).** Cyp2B6 activity evaluated by hydroxylation of bupropion in response to inhibition by ThioTEPA or induction by rifampin. **I)** Cyp2C19 activity evaluated by S-mephenytoin metabolism was undetectable in donor A, but could be inhibited by omeprazole or induced

by rifampin in donor B. J) CYP2D6 activity evaluated by Dextromethorphan could be inhibited by Quinidine in donor A, but was not detected in donor B.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 2. Integrating microtissues on-chip

A) For on-chip perfusion of microtissues, topographically patterned polydimethylsiloxane devices were designed with trap-like features of 500μm. Inset shows magnification of traps filled with empty PEG microtissues. B–D) Simulations of fluid flow were conducted for devices bearing traps of varied dimensions and spacing in order to visualize shear-protection offered by the traps in different configurations. C) Shear stress is maximal at the edge of each trap and is significantly less inside the traps. D) Spacing the traps further apart results in lower shear stress forces. E) In the optimal configuration, on average, each trap holds 11 microtissues, with 201 traps per device. F) Simulation of the point shear stress in the device at different flow rates. Shear stress was determined using the product of the shear rate and dynamic viscosity, where shear rate was calculated from the gradient of the velocity vector. G) Microtissues on-chip are functionally stable under different flow rates. Functionality, represented by the total amount of secreted albumin per device per day, was normalized to day 1 values. H–I) Un-encapsulated hepatocyte/3T3-J2 aggregates on chip. Before aggregation, 3T3-J2 cells were growth arrested with mitomycin C (10 μg/mL, 2hrs). Devices were perfused with medium at 24μl/hr or 540μl/hr. Bars represent the average albumin levels of three devices. Error bars represent standard error. Images were taken after one week of

perfusion. J) Long term on-chip functionality is shown by robust albumin production for 28 days in microtissues derived from two different donors, perfused at 24 μ l/hr. K) Rate of coumarin 7-hydroxylation by microtissues cultured in strainers (static) compared to metabolism rate in one pass through an equal amount of microtissues on chip. Values represent averages of biological triplicates, error bars represent standard deviation.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript




Figure 3. Differentiation of iPS cells to hepatocytes in 3D

A) Hepatocyte differentiation protocol. Cells were dissociated and aggregated in pyramidal microwells at different days of their differentiation. B) Albumin secretion of the 3D aggregates was compared to the original differentiation protocol in 2D. Lifting cells off and aggregating them during the hepatic specification phase yielded functional iHeps in 3D, whereas aggregation during the hepatoblast expansion or hepatic maturation phase yielded microtissues with reduced functionality. C–D) When dissociated at day 8, hepatic specified iPS cells form compact aggregates in 400 μm aggregewells. D) Aggregates at day 22 of differentiation express markers specific for hepatocytes (HNF4α, albumin) and for bile duct cells (HNF1β). Scale bars in C and D represent 100 μm.




Figure 4. Functional iPSC derived hepatocytes in 3D

A–B) Inducibility of CYP activity in primary hepatocyte microtissues and in iHep aggregates. Cells were treated with CYP inducers or control media for 72 hours. Microtissues with primary hepatocytes were cultured in strainers, and induction started at day 5 after encapsulation. iHep aggregates were cultured in aggrewwells and induction was started at day 19 of the differentiation. CYP activity was evaluated using luminescent substrates specific for either CYP1A1 or CYP2C9. A) CYP1A1 activity, evaluated by luciferin-CEE, could be induced with Omeprazole. B) CYP2C9 activity, evaluated by luciferin-H, could be induced with Rifampin. Values represent averages of biological triplicates, error bars show standard deviation.

C) Hepatocyte differentiation protocol. After dissociation and aggregation at day 8, iHep aggregates were encapsulated into PEG-DA hydrogels and trapped in a microfluidic device at day 12 of differentiation. D) Encapsulated iHep aggregates were viable as shown by Calcein AM (green; live) and Propidium Iodide (red; dead). E) Encapsulated iPS derived hepatic microtissues show long term albumin secretion on-chip. Values represent average albumin secretion per day of three different devices, normalized to the amount of cells. Number of cells was estimated based on the number of cells seeded in aggrewwells on day 8. Error bars represent standard deviation. Scale bars in represent 100 μ m.